Together, these reports indicate that miR-342 is not only a potential biomarker for ER+ breast cancer patient survival and tamoxifen efficacy, but also may serve as a therapeutic target to enhance patient responses to tamoxifen. Here, ESR1 is linked to breast carcinoma.